Curatis, 'Global Bio Talent Training Hub' Trainees Visit Companies for Education

Trainees from the WHO Workforce Training Hub are taking a commemorative photo at the Curatis Osong Bio Plant.
[Photo by Curatis]

[Asia Economy Reporter Lee Gwanju] Curatis announced on the 8th that it was designated as a vaccine manufacturing company facility tour site for the '2022 Basic Education on Quality Management of Vaccines and Biopharmaceuticals (GxP Course),' part of the Global Bio Workforce Training Hub program supported by the World Health Organization (WHO), and conducted the training.

The GxP course is conducted with the aim of strengthening the capabilities of biopharmaceutical production experts with over six years of experience in about 30 low- and middle-income countries (LMICs) including Korea, Indonesia, Malaysia, and Vietnam. Korea was designated as a global bio workforce training hub by WHO in February this year.

Curatis provided approximately 40 trainees with a tour of its own production facilities at the Osong Bio Plant, including production and research facilities, and explained the production processes of the adolescent and adult tuberculosis vaccines and next-generation mRNA COVID-19 vaccines currently under development. In addition, through this company visit program, participants from bioindustry-related government departments who visited with the trainees highly evaluated the global-level production facilities of the Osong Bio Plant.

The Osong Bio Plant has obtained GMP (Good Manufacturing Practice) certification and is capable of producing sterile injectable finished pharmaceuticals in both liquid and lyophilized forms. Currently, the liquid formulation can be produced at a scale of up to 50 million vials annually, and with additional production facility expansion, the production capacity is expected to increase to over 200 million vials annually based on finished pharmaceuticals.

Jo Gwan-gu, CEO of Curatis, said, "This training course was a meaningful time that could contribute to bio workforce development," adding, "We will continue to take the lead in sharing Curatis’ excellent vaccine development and production know-how to help resolve the imbalance in vaccine supply."

This content was produced with the assistance of AI translation services.